An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects

Healthy Clinical Trial

Official title:

An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-NW-3509 in Healthy Male Subjects

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03446274
• Other study ID #: NW3509-007
• Status: Recruiting
• Phase: Phase 1
• Start date: April 2, 2018
• Est. completion date: June 2018

Study information

• Verified date: June 2018
• Source: Newron Pharmaceuticals SPA
• Contact: Ravi Anand, MD
• Phone: +41 793741364
• Email: ravi[@]anand.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, open-label, non-randomized, single dose of 14C-NW-3509 capsule study in 6 healthy male subjects.

Description:

This is a single-center, open-label, non-randomized, single dose study in a single cohort of 6 healthy male subjects, including up to 2 cytochrome P450 (CYP)2D6 poor metabolizer subjects. Each subject will receive a single oral administration of 14C-NW-3509 capsule in the fasted state.The screening period and study admission to completion is estimated to be up to 43 days. The following data will be analyzed urine and feces data for total radioactivity, plasma and whole blood data for total radioactivity and plasma concentration data for NW-3509.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 6
• Est. completion date: June 2018
• Est. primary completion date: April 23, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 30 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Healthy males

2. Body mass index of 18.0 to 35.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator

3. Must be willing and able to communicate and participate in the whole study

4. Must have regular bowel movements (ie, average stool production of =1 and =3 stools per day)

5. Subject is considered healthy on the basis of medical history, physical examination, ECG, vital signs and clinical laboratory assessments

6. Must provide written informed consent

7. Must adhere to the contraception requirements

Exclusion Criteria:

1. Subjects who have received any IMP in a clinical research study within the previous 3 months

2. Subjects who are study site employees, or immediate family members of a study site or sponsor employee

3. Subjects who have previously been enrolled in this study

4. History of any drug or alcohol abuse in the past 2 years

5. Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)

6. Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening and admission

7. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months

8. Radiation exposure, excluding background radiation but including significant medical exposures, or other trial related exposures, not exceeding 5 mSv in the 12 months preceding participation in the trial, or radiation exposure exceeding 10 mSv in the 5 years preceding participation in the trial, inclusive of the 3 mSv exposure resulting from participation in this study. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study. Significance of a medical exposure will be determined by the investigator.

9. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening

10. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator (laboratory parameters are listed in Appendix 1)

11. Positive drugs of abuse test result (drugs of abuse tests are listed in Appendix 1)

12. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results

13. History of cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, or neurological or psychiatric disorder, as judged by the investigator

14. Presence or history of seizure disorders or ataxia

15. History of presence of significant cardiac conduction abnormalities including but not limited to: PR interval >240 msec; QRS duration >120 msec; QTcF interval >450 msec

16. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients

17. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active

18. Donation or loss of greater than 400 mL of blood within the previous 3 months

19. Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 4 g per day paracetamol) or herbal remedies in the 14 days before IMP administration (See Section 11.4). Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the PI and sponsor's medical monitor.

20. Failure to satisfy the investigator of fitness to participate for any other reason

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Evenamide
This is an orally available small molecule that potently blocks voltage-gated sodium channels (VGSCs) in vitro and is indicated for the treatment of patients with schizophrenia, mania, and bipolar disorder.

Locations

Country	Name	City	State
United Kingdom	Quotient Sciences	Nottingham	NG

Sponsors (1)

Lead Sponsor	Collaborator
Newron Pharmaceuticals SPA

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Metabolic profiling for NW-3509 will be determined in plasma, urine and fecal samples	Percent of each radio labeled drug-related material will be determined in plasma, urine and feces	15 days
Secondary	Routes and rate of elimination of NW-3509 in plasma, urine and feces	The routes and rate of elimination of 14C-NW-3509 by measurement of 14C-NW-3509 and its major metabolites in plasma, urine and feces	15 days
Secondary	The identification of major metabolites of NW-3509 in plasma, urine and feces	Metabolic profiling will be performed using liquid chromatography-radio-detection, with subsequent mass spectrometry	15 days
Secondary	Safety and Tolerability of NW-3509	This will be assessed by Adverse events, Clinical chemistry, Clinical Hematology and Urinalysis, Vital signs and Physical Examination	15 days
Secondary	Oral Pharmacokinetics of NW-3509 in plasma, urine and feces	Several parameters will be measured Cmax, Tmax, AUC, elimination half-life, Tlag etc	15 days